Whitehawk Therapeutics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
WHWK
- Investments
-
1
- Share Price
-
$3.06
- (As of Friday Closing)
Whitehawk Therapeutics General Information
Description
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Contact Information
Website
www.whitehawktx.comCorporate Office
- 2 Headquarters Plaza
- East Building, 11th Floor
- Morristown, NJ 07960
- United States
Corporate Office
- 2 Headquarters Plaza
- East Building, 11th Floor
- Morristown, NJ 07960
- United States
Whitehawk Therapeutics Timeline
Whitehawk Therapeutics Stock Performance
As of 13-Nov-2026, Whitehawk Therapeutics’s stock price is $3.06. Its current market cap is $181M with 59M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.06 | $3.07 | $1.97 - $5.50 | $181M | 59M | 339K | -$1.07 |
Whitehawk Therapeutics Financials Summary
As of 30-Sep-2026, Whitehawk Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 24,372 | (48,546) | 16,195 | (68,424) |
| Revenue | 0 | 7,145 | 25,983 | 24,354 |
| EBITDA | (89,442) | (26,748) | (67,269) | (71,765) |
| Net Income | (83,294) | (20,596) | (63,691) | (65,765) |
| Total Assets | 173,686 | 150,830 | 70,319 | 132,423 |
| Total Debt | 218 | 0 | 833 | 1,267 |
Whitehawk Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Whitehawk Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Whitehawk Therapeutics Comparisons
Industry
Financing
Details
Whitehawk Therapeutics Competitors (47)
One of Whitehawk Therapeutics’s 47 competitors is Abeona Therapeutics, a Corporation company based in Cleveland, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| ABIONYX Pharma | Formerly VC-backed | Balma, France | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Gossamer Bio | Formerly VC-backed | San Diego, CA |
Whitehawk Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Whitehawk Therapeutics Patents
Whitehawk Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4823571-A1 | Methods of treating a cancer in an individual | Pending | 14-Dec-2023 | ||
| WO-2025129108-A1 | Methods of treating a cancer in an individual | Inactive | 14-Dec-2023 | ||
| WO-2025049962-A1 | Combination cancer treatments with a composition comprising an mtor pathway inhibitor | Inactive | 31-Aug-2023 | ||
| EP-4757806-A1 | Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers | Pending | 08-Aug-2023 | ||
| US-20260315437-A1 | Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers | Pending | 08-Aug-2023 | A61K31/4196 |
Whitehawk Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Whitehawk Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Whitehawk Therapeutics Acquisitions (1)
Whitehawk Therapeutics’s most recent deal was a Merger/Acquisition with Aerpio. The deal was made on 26-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aerpio | 26-Aug-2021 | Merger/Acquisition | Drug Discovery |
Whitehawk Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.33 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Whitehawk Therapeutics FAQs
-
When was Whitehawk Therapeutics founded?
Whitehawk Therapeutics was founded in 2007.
-
Where is Whitehawk Therapeutics headquartered?
Whitehawk Therapeutics is headquartered in Morristown, NJ.
-
What is the size of Whitehawk Therapeutics?
Whitehawk Therapeutics has 23 total employees.
-
What industry is Whitehawk Therapeutics in?
Whitehawk Therapeutics’s primary industry is Drug Discovery.
-
Is Whitehawk Therapeutics a private or public company?
Whitehawk Therapeutics is a Public company.
-
What is Whitehawk Therapeutics’s stock symbol?
The ticker symbol for Whitehawk Therapeutics is WHWK.
-
What is the current stock price of Whitehawk Therapeutics?
As of 13-Nov-2026 the stock price of Whitehawk Therapeutics is $3.06.
-
What is the current market cap of Whitehawk Therapeutics?
The current market capitalization of Whitehawk Therapeutics is $181M.
-
Who are Whitehawk Therapeutics’s competitors?
Abeona Therapeutics, ABIONYX Pharma, Gilead, Genentech, and Gossamer Bio are some of the 47 competitors of Whitehawk Therapeutics.
-
What is Whitehawk Therapeutics’s annual earnings per share (EPS)?
Whitehawk Therapeutics’s EPS for 12 months was -$1.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
